Liu Min, Liang Tian, Zhang Peiying, Zhang Qing, Lu Lei, Wang Zhongliang
Min Liu, Xuzhou City Hospital of TCM, Xuzhou 221009, Jiangsu Province, China, Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
Tian Liang, Xuzhou City Hospital of TCM, Xuzhou 221009, Jiangsu Province, China, Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
Pak J Med Sci. 2017 Jul-Aug;33(4):920-925. doi: 10.12669/pjms.334.13059.
To explore hsCRP and ET-1 expressions in patients with no-reflow phenomenon after percutaneous coronary intervention (PCI).
A total of 136 patients with single coronary artery disease receiving PCI were divided into a reflow group and a no-reflow group to compare the level use of ET-1 alone with combined level of ET-1 and hs-CRP in PCI regarding sensitivity, specificity, positive and negative predictive values and accuracy for postoperative no-reflow. The study was conducted between 2014-2016 at our hospital.
Postoperative levels of ET-1 and hs-CRP in no-reflow group were significantly higher than those of reflow group (P<0.05). ET-1 level of reflow group peaked three hours after PCI and then declined. Serum level of hs-CRP decreased most obviously within three hours after PCI in reflow group and three hours - three days after PCI in no-reflow group. Left ventricular end-diastolic diameters of both groups after PCI were apparently lower than those before PCI, without significant inter-group difference (P>0.05). Left ventricular end-systolic diameters and left ventricular ejection fractions of both groups evidently increased after PCI, without significant inter-group differences either (P>0.05). Corrected TIMI frame count (CTFC) and wall motion score index of reflow group after PCI were significantly lower than those of no-reflow group (P<0.05). ET-1 level was positively correlated with CTFC (P<0.05). Multivariate linear regression showed hs-CRP was negatively correlated with the serum level (P<0.05) (r=-0.34).
hsCRP and ET-1 levels significantly increased in patients with no-reflow phenomenon.
探讨经皮冠状动脉介入治疗（PCI）后无复流现象患者血清超敏C反应蛋白（hsCRP）及内皮素-1（ET-1）的表达情况。
选取136例接受PCI治疗的单支冠状动脉疾病患者，分为复流组和无复流组，比较PCI术后单独使用ET-1及联合使用ET-1与hs-CRP对术后无复流现象的敏感度、特异度、阳性预测值、阴性预测值及准确度。本研究于2014年至2016年在我院开展。
无复流组术后ET-1及hs-CRP水平显著高于复流组（P<0.05）。复流组ET-1水平在PCI术后3小时达峰值，随后下降。复流组hs-CRP血清水平在PCI术后3小时内下降最明显，无复流组在PCI术后3小时至3天下降最明显。两组PCI术后左心室舒张末期内径均明显低于术前，组间差异无统计学意义（P>0.05）。两组PCI术后左心室收缩末期内径及左心室射血分数均明显增加，组间差异无统计学意义（P>0.05）。复流组PCI术后校正的心肌梗死溶栓试验帧数（CTFC）及室壁运动评分指数明显低于无复流组（P<0.05）。ET-1水平与CTFC呈正相关（P<0.05）。多因素线性回归分析显示hs-CRP与血清水平呈负相关（P<0.05）（r=-0.34）。
无复流现象患者hsCRP及ET-1水平显著升高。
